WallStreetZenWallStreetZen

NASDAQ: MGX
Metagenomi Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for MGX

Based on 3 analysts offering 12 month price targets for Metagenomi Inc

Min Forecast
$7.00+332.1%
Avg Forecast
$11.67+620.19%
Max Forecast
$16.00+887.65%

Should I buy or sell MGX stock?

Based on 3 analysts offering ratings for Metagenomi Inc.

Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although MGX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates MGX as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -8.02% per year. Learn More

Be the first to know when Wall Street analysts revise their MGX stock forecasts and price targets.

MGX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-05-15
lockedlocked$00.00+00.00%2025-05-14
lockedlocked$00.00+00.00%2025-04-03

1 of 1

Forecast return on equity

Is MGX forecast to generate an efficient return?

Company
-54.14%
Industry
148.05%
Market
89.88%
MGX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MGX forecast to generate an efficient return on assets?

Company
-38.65%
Industry
39.47%
MGX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MGX earnings per share forecast

What is MGX's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$2.42
Avg 2 year Forecast
-$1.74
Avg 3 year Forecast
-$2.85

MGX revenue forecast

What is MGX's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$34.4M-24.07%
Avg 2 year Forecast
$42.3M-6.65%
MGX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

MGX revenue growth forecast

How is MGX forecast to perform vs Biotechnology companies and vs the US market?

Company
-16.04%
Industry
58.7%
Market
9.75%
MGX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
MGX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

MGX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MGX$1.62$11.67+620.19%Strong Buy
IRD$1.02$7.00+586.27%Buy
NTRB$5.48$13.00+137.23%Buy
ABOS$1.02$7.50+635.29%Strong Buy
CNTX$0.69$6.00+765.80%Strong Buy
View Top Biotech Stocks

Metagenomi Stock Forecast FAQ

Is Metagenomi Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: MGX) stock is to Strong Buy MGX stock.

Out of 3 analysts, 2 (66.67%) are recommending MGX as a Strong Buy, 1 (33.33%) are recommending MGX as a Buy, 0 (0%) are recommending MGX as a Hold, 0 (0%) are recommending MGX as a Sell, and 0 (0%) are recommending MGX as a Strong Sell.

If you're new to stock investing, here's how to buy Metagenomi stock.

What is MGX's earnings growth forecast for 2025-2027?

(NASDAQ: MGX) Metagenomi's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.7%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.47%.

Metagenomi's earnings in 2025 is -$77,949,000.On average, 5 Wall Street analysts forecast MGX's earnings for 2025 to be -$90,388,455, with the lowest MGX earnings forecast at -$115,882,635, and the highest MGX earnings forecast at -$53,829,353. On average, 4 Wall Street analysts forecast MGX's earnings for 2026 to be -$65,043,801, with the lowest MGX earnings forecast at -$106,537,261, and the highest MGX earnings forecast at -$24,297,972.

In 2027, MGX is forecast to generate -$106,537,261 in earnings, with the lowest earnings forecast at -$106,537,261 and the highest earnings forecast at -$106,537,261.

What is MGX's revenue growth forecast for 2025-2026?

(NASDAQ: MGX) Metagenomi's forecast annual revenue growth rate of -16.04% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 58.7%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.75%.

Metagenomi's revenue in 2025 is $45,263,000.On average, 3 Wall Street analysts forecast MGX's revenue for 2025 to be $1,284,801,983, with the lowest MGX revenue forecast at $617,168,482, and the highest MGX revenue forecast at $1,741,977,667.

In 2026, MGX is forecast to generate $1,579,555,071 in revenue, with the lowest revenue forecast at $617,168,482 and the highest revenue forecast at $2,541,941,660.

What is MGX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: MGX) forecast ROA is -38.65%, which is lower than the forecast US Biotechnology industry average of 39.47%.

What is MGX's Price Target?

According to 3 Wall Street analysts that have issued a 1 year MGX price target, the average MGX price target is $11.67, with the highest MGX stock price forecast at $16.00 and the lowest MGX stock price forecast at $7.00.

On average, Wall Street analysts predict that Metagenomi's share price could reach $11.67 by May 15, 2026. The average Metagenomi stock price prediction forecasts a potential upside of 620.19% from the current MGX share price of $1.62.

What is MGX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: MGX) Metagenomi's current Earnings Per Share (EPS) is -$2.11. On average, analysts forecast that MGX's EPS will be -$2.42 for 2025, with the lowest EPS forecast at -$3.10, and the highest EPS forecast at -$1.44. On average, analysts forecast that MGX's EPS will be -$1.74 for 2026, with the lowest EPS forecast at -$2.85, and the highest EPS forecast at -$0.65. In 2027, MGX's EPS is forecast to hit -$2.85 (min: -$2.85, max: -$2.85).

What is MGX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: MGX) forecast ROE is -54.14%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.